Cosimo Commisso Archives - Sanford Burnham Prebys
Institute News

Two Sanford Burnham Prebys scientists selected for American Cancer Society postdoctoral fellowships

AuthorGreg Calhoun
Date

October 18, 2024

Funds will support Alicia Llorente Lope and Ambroise Manceau who study breast and pancreatic cancer

Alicia Llorente Lope, PhD, and Ambroise Manceau, PhD, were awarded 2024 Postdoctoral Fellowships from the American Cancer Society (ACS). These prestigious awards provide more than $65,000 per year for up to three years to support early career scientists studying cancer.

“I was so excited when I heard the news,” said Llorente. “It is a privilege to have this award, and it feels very validating to know that someone saw enough potential in my research to deem it worthy of funding.”

Tackling treatment-resistant breast cancer

Llorente joined the lab of Brooke Emerling, PhD, director of the Cancer Metabolism and Microenvironment Program at Sanford Burnham Prebys, nearly three years ago after beginning her breast cancer research career as a doctoral student.

“I was first interested in breast cancer because my grandmother died of the disease, and I wanted to contribute to finding new therapeutic opportunities for cancer patients,” said Llorente. Llorente’s ACS-funded research project focuses on HER2-positive (HER2+) breast cancer.

Roughly one in five breast cancer tumors have elevated levels of the HER2 protein. While these tumors tend to grow quickly, drugs targeting the HER2 protein are usually effective at first. However, HER2+ tumors often are able to adapt and develop resistance to these drugs over time, leaving patients with few if any remaining treatments options.

Llorente has found evidence that a form of the protein phosphatidylinositol-5-phosphate 4-kinase (PI5P4K) plays a role in breast cancer tumors becoming resistant to HER2 drugs.

Brooke Emerling

Brooke Emerling, PhD

“We’ve revealed a strong connection between elevated levels of PI5P4K gamma and reduced survival rates in patients with HER2+ breast cancer,” explained Llorente. “I plan to explore whether targeting both HER2 and PI5P4K gamma in breast cancer cells may provide a path to overcoming treatment resistance.” Llorente also will study the functions of PI5P4K gamma in breast cancer cells to see why these cells cease to respond to HER2-targeting drugs.

“I am incredibly proud of Alicia for spearheading this groundbreaking project targeting the lipid kinase PI5P4K gamma,” said Emerling. “Her insightful analysis of breast cancer datasets, which uncovered a correlation between elevated expression of PI5P4K gamma and worse outcomes in HER2+ patients, has set the stage for vital research aimed at overcoming the significant challenge of resistance to targeted therapies in HER2+ tumors.”

Cosimo Commisso headshot

Cosimo Commisso, PhD

Powering down pancreatic cancer

Manceau is in the second year of his postdoctoral training in the lab of Cosimo Commisso, PhD, interim director and deputy director of the institute’s NCI-Designated Cancer Center. During his doctoral program, Manceau studied how abnormal cells die in a programmed series of steps called apoptosis, a process known to go awry in cancer and neurodegenerative diseases.

“It began as a basic science project about the molecular processes around cell death, and over time it led to possible therapeutic implications,” said Manceau. “I learned that I like to study fundamental biology and then try to find an application for it, and I saw in the Commisso lab an opportunity to do just that in pancreatic cancer.”

Manceau’s fellowship project focuses on pancreatic ductal adenocarcinoma (PDAC) — the most common form of pancreatic cancer with only a 13% five-year survival rate — and its ravenous pursuit of energy. Because of PDAC cells’ constant need for fuel to sustain their rampant growth, they adapt by reshaping the surface of their cells to snatch extra nutrients from the jelly-like substance between cells.

Commisso and others have shown that cutting off the extra power supplied by this process — known as macropinocytosis — reduces tumor growth. Manceau has studied the contents taken by contorted pancreatic cell surfaces in pockets called macropinosomes. By analyzing every single protein in this scooped goop, he found that calcium transporter proteins present in macropinosomes also are required for macropinocytosis.

“During the fellowship, I will work to understand how these transporter proteins affect macropinocytosis,” said Manceau. “These proteins have never been targeted before in pancreatic cancer, so our long-term goal is to use this strategy to cut the nutrient supply to tumors and see if we can inhibit tumor growth.”

“By disrupting the cancer cells’ ability to feed themselves through macropinocytosis, we can potentially starve tumors and inhibit their growth,” added Commisso. “Ambroise’s research aims to target key proteins involved in this process, opening up new possibilities for treatments that could significantly improve outcomes for patients battling pancreatic cancer.”

Institute News

Pancreatic cancer symposium celebrates 10th anniversary in San Diego

AuthorGreg Calhoun
Date

May 22, 2024

The 2024 PancWest Symposium brought more than 120 scientists to the Sanford Burnham Prebys campus in San Diego to discuss the latest advances in pancreatic cancer research.

More than 120 pancreatic cancer researchers from the West Coast traveled to San Diego from as far as Vancouver to attend the 2024 PancWest Symposium on May 17. The PancWest Symposium was founded in 2014 to regularly bring the scientific community studying pancreatic cancer together to discuss advances in the field and foster new collaborations.

The PancWest Symposium is held every two years in a different city to showcase expert scientists who are making important contributions to the field of pancreatic cancer research, including tumorigenesis, tumor progression and the discovery of novel therapeutic paradigms, such as immunomodulation and metabolic targeting.

The 2024 event was held on the Sanford Burnham Prebys campus in the Fishman Auditorium and was hosted by Cosimo Commisso, Ph.D., director of, and associate professor in, the Institute’s Cancer Metabolism and Microenvironment Program; and Pamela Itkin-Ansari, Ph.D., adjunct professor in the Institute’s Development, Aging and Regeneration Program.

“While pancreatic cancer accounts for only three percent of cancer cases, it has the highest mortality rate among major cancers and is the third leading cause of cancer-related death in the U.S.,” says Commisso.

PancWest Symposium poster presentations in Chairmen's Hall

The symposium’s events included a keynote address, 12 featured speakers, a poster session and a series of “power talks” providing attendees a chance to hear two-minute oral presentations from selected poster presenters.

“Unless we find ways to better diagnose and treat this disease, it is projected to become the second most deadly cancer in less than 20 years,” adds Itkin-Ansari. “That is why events such as PancWest are so important to enhance innovation and foster collaboration.”

Rosalie C. Sears, Ph.D., professor of Molecular and Medical Genetics, co-director of the Brenden-Colson Center for Pancreatic Care and Krista L. Lake Chair in Cancer Research at Oregon Health & Science University in Portland, gave the symposium’s keynote address.

Additional events at the symposium included 12 featured speakers, a poster session and a series of “power talks” providing attendees a chance to hear two-minute oral presentations from selected poster presenters.

“Being a part of PancWest has been a transformative experience,” shares Itkin-Ansari. “The exchange of groundbreaking research and innovative ideas among leading experts advanced our scientific understanding.”

“It also paved the way for new therapeutic strategies, ultimately offering hope and improved outcomes for patients battling pancreatic cancer,” adds Commisso.

More information about the symposium and featured speakers is available on the event’s webpage.

Institute News

Behind the scenes at Sanford Burnham Prebys’ Cancer Center

AuthorMiles Martin
Date

March 28, 2023

Cancer Center open house connects San Diego community with scientists working toward cancer cures

The Institute’s NCI-designated Cancer Center hosted an open house to showcase the latest research advances in cancers of the digestive system. The event was sponsored by the center’s Community Advisory Board (CAB), which provides a link to community networks of people—including patients, survivors and their loved ones.

“These events are especially helpful for people affected by cancer because our researchers can explain the science behind the disease and the approaches we use to find new treatments,” says Associate Professor Cosimo Commisso, PhD, who co-hosted the event with Adjunct Associate Professor Pamela Itkin-Ansari, PhD “As researchers, it’s critical that we have community participation to influence our research—so we benefit as well.” 

The open house, which was free to the public, fulfills a key part of the CAB’s mission—to create awareness of the cancer research being done at the Institute and to promote dialogue between its scientists and the community. Guests had the chance to mingle with cancer researchers, and there was also a panelist table, where they could ask questions directly to a panel including two cancer survivors and a clinician.

The theme of the open house was cancers of the digestive system, which includes pancreatic cancer, liver cancer, stomach cancer and colorectal cancer. Although these cancers are very diverse, one thing many cancers of the digestive system have in common is that they take a long time to diagnose and are difficult to treat. 

“These are devastating cancers,” says Commisso. “We’ve doubled the survival rates for pancreatic cancer since I started working in this field over a decade ago, but it’s still only around 10%. And that’s just not good enough.”

Attendees also got behind-the-scenes tours of labs, including Commisso’s, where researchers are working to halt pancreatic cancer by blocking nutrients—in essence, starving tumor cells of the fuel they need to grow and proliferate. 

“We have a lot of researchers taking different approaches to cancer here at the Institute, and it’s important for people affected by cancer to know that while we’re still a long way off from ending cancer forever, we’re still making progress,” adds Commisso.

Institute News

Our top 10 discoveries of 2020

AuthorMonica May
Date

December 14, 2020

This year required dedication, patience and perseverance as we all adjusted to a new normal—and we’re proud that our scientists more than rose to the occasion.

Despite the challenges presented by staggered-shift work and remote communications, our researchers continued to produce scientific insights that lay the foundation for achieving cures.

Read on to learn more about our top 10 discoveries of the year—which includes progress in the fight against COVID-19, insights into treating deadly cancers, research that may help children born with a rare condition, and more.

  1. Nature study identifies 21 existing drugs that could treat COVID-19

    Sumit Chanda, PhD, and his team screened one of the world’s largest drug collections to find compounds that can stop the replication of SARS-CoV-2. This heroic effort was documented by the New York Times, the New York Times Magazine, TIME, NPR and additional outlets—and his team continues to work around the clock to advance these potential treatment options for COVID-19 patients.

  2. Fruit flies reveal new insights into space travel’s effect on the heart

    Wife-and-husband team Karen Ocorr, PhD, and Rolf Bodmer, PhD, shared insights that hold implications for NASA’s plan to build a moon colony by 2024 and send astronauts to Mars.

  3. Personalized drug screens could guide treatment for children with brain cancer

    Robert Wechsler-Reya, PhD, and Jessica Rusert, PhD, demonstrated the power of personalized drug screens for medulloblastoma, the most common malignant brain cancer in children.

  4. Preventing pancreatic cancer metastasis by keeping cells “sheltered in place”

    Cosimo Commisso, PhD, identified druggable targets that hold promise as treatments that stop pancreatic cancer’s deadly spread.

  5. Prebiotics help mice fight melanoma by activating anti-tumor immunity

    Ze’ev Ronai, PhD, showed that two prebiotics, mucin and inulin, slowed the growth of melanoma in mice by boosting the immune system’s ability to fight cancer.

  6. New test for rare disease identifies children who may benefit from a simple supplement

    Hudson Freeze, PhD, helped create a test that determines which children with CAD deficiency—a rare metabolic disease—are likely to benefit from receiving a nutritional supplement that has dramatically improved the lives of other children with the condition.

  7. Drug guides stem cells to desired location, improving their ability to heal

    Evan Snyder, MD, PhD, created the first drug that can lure stem cells to damaged tissue and improve treatment efficacy—a major advance for regenerative medicine.

  8. Scientists identify a new drug target for dry age-related macular degeneration (AMD)

    Francesca Marassi, PhD, showed that the blood protein vitronectin is a promising drug target for dry age-related macular degeneration (AMD), a leading cause of vision loss in Americans 60 years of age and older.

  9. Scientists uncover a novel approach to treating Duchenne muscular dystrophy

    Pier Lorenzo Puri, MD, PhD, collaborated with scientists at Fondazione Santa Lucia IRCCS and Università Cattolica del Sacro Cuore in Rome to show that pharmacological (drug) correction of the content of extracellular vesicles released within dystrophic muscles can restore their ability to regenerate muscle and prevent muscle scarring.

  10. New drug candidate reawakens sleeping HIV in the hopes of a functional cure

    Sumit Chanda, PhD, Nicholas Cosford, PhD, and Lars Pache, PhD, created a next-generation drug called Ciapavir (SBI-0953294) that is effective at reactivating dormant human immunodeficiency virus (HIV)—an approach called “shock and kill.”

Institute News

Starving the “world’s toughest cancer”

AuthorMonica May
Date

November 18, 2019

Russell Gold is lucky to be alive. Only 9% of people with pancreatic cancer survive longer than five years—making it one of the deadliest cancers. This January, he will be a six-year survivor. 

To help the public better understand what makes pancreatic cancer so lethal—and how we can develop medicines so there are “more of me,” as Gold said—our Institute teamed up with the Fleet Science Center to host a panel discussion on Sunday, November 17. Gold was joined by a clinician and a scientist who both work on pancreatic cancer: Darren Sigal, MD, of Scripps Health; and Cosimo Commisso, Ph.D., an assistant professor at Sanford Burnham Prebys’ National Cancer Institute (NCI)-designated Cancer Center, respectively. 

As the speakers explained, pancreatic cancer is often difficult to diagnose because symptoms—such as pain in the abdomen, yellow skin and eyes, and weight loss—do not typically occur until the disease is advanced. As a result, pancreatic cancer is the 11th most common cancer but the second-leading cause of cancer death. More than 56,000 Americans are expected to receive a pancreatic cancer diagnosis in 2019, according to the American Cancer Society. 

Commisso, who was recently named a NextGen Star by the American Association for Cancer Research, is hopeful that his research will lead to effective treatments for pancreatic cancer. Commisso’s research focuses on how rapidly growing pancreatic tumors scavenge nutrients using an alternative supply route, called macropinocytosis. His lab has found that blocking this process, often described as “cellular drinking,” causes pancreatic tumors to shrink—indicating that the approach could lead to tumor-starving drugs. 

This event was the fourth of our five-part “Cornering Cancer” series. Register today to join us for a discussion on pediatric brain cancer in December.

Institute News

AACR selects Sanford Burnham Prebys scientist as NextGen Star

AuthorMonica May
Date

April 4, 2019

The American Association for Cancer Research (AACR) has named Cosimo Commisso, PhD, assistant professor in Sanford Burnham Prebys’ NCI-designated Cancer Center, as a NextGen Star. 

The program strives to increase the visibility of early career scientists at the organization’s annual meeting—one of the year’s largest gatherings of cancer researchers—and to support their professional development and advancement. The 2019 AACR Annual Meeting was held from March 29 to April 3 in Atlanta and attracted more than  21,000 scientists and clinicians. 

As a NextGen star, Commisso was featured on AACR’s website and was invited to give a presentation during a special “NextGen Star” session. He also presented in a session titled, “Features and Functions of the Pancreatic Tumor Microenvironment.” Both talks were well attended.

Commisso’s presentations focused on pancreatic cancer, a deadly and difficult-to-detect tumor. Less than 10 percent of people who are diagnosed with pancreatic cancer are alive five years later. More than 56,000 Americans are expected to be diagnosed with pancreatic cancer in 2019 and its incidence is on the rise. Pancreatic cancer is on track to become the second leading cause of cancer-related death in the U.S. next year, according to the Pancreatic Cancer Action Network. New studies have linked military service to an increased risk of pancreatic cancer, perhaps due to exposure to herbicides such as Agent Orange.

Commisso is working to halt pancreatic cancer growth by studying the way cells internalize nutrients, called macropinocytosis. In this process, cells extend their membranes to capture nutrients in their surrounding environment—similar to how humans swallow a pill by encasing it in water. 

“We’ve discovered that pancreatic tumors that have a mutation in the RAS gene—which occurs in almost all cases—fuel their growth by kicking macropinocytosis into overdrive,” says Commisso. “By halting macropinocytosis, essentially cutting off the cancer cells’ fuel supply, we hope we can develop effective, much-needed treatments for pancreatic cancer.”

In his NextGen Star presentation, Commisso detailed how macropinocytosis is dialed up or down depending on nutrient availability. Studies performed by Szu-Wei Lee, PhD, a postdoctoral fellow in the Commisso laboratory, indicate that RAS-mutated pancreatic tumors use two forms of macropinocytosis—one that is “always on” (constitutive) and another that is nutrient dependent.

“Uncovering the molecular differences between these two pathways could yield personalized targets that selectively target pancreatic cancer cells,” says Commisso. “In addition to pancreatic tumors, new evidence shows that lung, prostate and bladder cancers highjack macropinocytosis to keep growing. This means our work in pancreatic cancer may also lead to new treatments for these other tumor types.”

Watch Dr. Commisso explain his lab’s focus

View the full list of the NextGen stars 

Interested in keeping up with SBP’s latest discoveries, upcoming events and more? Subscribe to our monthly newsletter, Discoveries below.

Institute News

Cosimo Commisso explains cancer metabolism on NIH website

AuthorJessica Moore
Date

June 7, 2016

The most deadly of all cancers are driven by mutations in a family of genes known as RAS. In a new article on the website for the National Cancer Institute’s RAS Initiative, Cosimo Commisso, PhD, assistant professor in SBP’s NCI-designated Cancer Center, discusses how the metabolism of cancer cells might be different in different parts of solid tumors.

The RAS Initiative is a collaborative effort to explore innovative approaches for attacking the proteins encoded by mutant forms of RAS genes, which drive 30% of human cancers.

Institute News

SBP presents at American Association for Cancer Research’s annual meeting

AuthorKristen Cusato
Date

May 10, 2016

Deputy Director of the NCI-designated Cancer Center, Jorge Moscat, PhD, and Cosimo Commisso, PhD, assistant professor in the Center, presented at the AACR conference in New Orleans.

Moscat presented at the session titled “Metabolic Interplay between Tumor and Microenvironment.”

“Cancer cells have to adapt their metabolism to survive nutrient deprivation and several stress conditions in their tumor microenvironment. For this they put in motion a process called autophagy whereby they get rid of toxic intracellular molecules and organelles and generate nutrients that allow them to survive,” said Moscat.

“Central to this process is a protein called p62 that was discovered in collaboration with my SBP colleague Maria Diaz-Meco. This protein is upregulated in, for example, liver cancer, whose mortality has increased dramatically over the last 10 years, in marked contrast to many other neoplasias that have shown a significant decrease in mortality.

“We presented new compelling data from human patients, mouse models and cell culture studies demonstrating that inactivation of p62 in cancer liver cells dramatically reduced the incidence and aggressiveness of hepatocellular carcinoma. Therefore, p62 is a novel and potentially actionable therapeutic target in liver cancer,” added Moscat.

Moscat said he was impressed at AACR by the number and quality of research studies linking the possibility of treating patients by a combined strategy of targeting cancer metabolism and the immunological tumor microenvironment.

He also spoke to ecancer.tv, an online provider of oncology news, about his research. Watch the video here.

Moscat is co-chair of a symposium on related research in cancer metabolism to that will be held June 22-23 at SBP’s La Jolla campus.

Commisso’s presentation was featured in a special session on pancreatic cancer that aimed to stimulate opportunities for collaboration between Pancreatic Cancer Action Network-AACR grantees and others in the field.

“The research that I presented was focused on a novel drug target in pancreatic cancer discovered recently by my lab,” said Commisso.

“We have found that an ion transporter that regulates pH homeostasis is critical to pancreatic cancer cell survival. This previously uncharacterized transporter plays a role in maintaining amino acid supply in tumor cells that harbor a mutation in the oncogene known as Ras, which is mutated in >90% of pancreatic tumors.

“Our future work is focused on exploring the role of this transporter in preclinical models and developing new approaches to inhibit this druggable target,” added Commisso.

He called the AACR meeting “a remarkable opportunity for cancer researchers to come together and share their exciting discoveries.”  Dr. Commisso also said it was a good opportunity to connect with colleagues and friends to develop and nurture scientific collaborations, to create, progress and build.

Commisso will also present at the 2016 PancWest Symposium in September at the Moores Cancer Center at UCSD.

Institute News

Happy Holidays from Sanford-Burnham!

Authorpbartosch
Date

December 23, 2014

As the year draws to a close, we look back on Sanford-Burnham’s many achievements in 2014. Over the year, our scientists published numerous papers in high-profile journals; secured significant grant funding; partnered with companies, institutes, and nonprofit organizations from across the country and the globe; and they took important steps toward our ultimate goal – to have a tangible impact on human health. Here are 14 accomplishments of 2014 that we are proud to share with you: Continue reading “Happy Holidays from Sanford-Burnham!”